Catalyst
Slingshot members are tracking this event:
Immune Design (IMDZ) to present interim data from LV305 Phase 1 expansion trial in NY-ESO-1-positive soft tissue sarcoma patients at ASCO 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IMDZ |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 05, 2016
Occurred Source:
http://www.immunedesign.com/wp-content/uploads/2016/06/LV305-ASCO-poster-2016-final-31May2016-v01.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Interim Data, Phase 1 Trial, Ny-eso-1 Cancers, Sarcoma, Lv305, Cytotoxic Nk Cells
